Vilanterol trifenatate Inhibitor

Vilanterol trifenatate is a long-acting agonist of beta2-adrenoceptor (beta2-AR) with inherent 24-hour activity(beta2-AR, beta1-AR and beta3-AR pEC50s of 10.37, 6.98 and 7.36, respectively)

Slack RJ, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013 Jan;344(1):218-30
Slack RJ, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013 Jan;344(1):218-30
Harrell AW, et al. Metabolism and disposition of Vilanterol, a long-acting beta(2)-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013 Jan;41(1):89-100.
Harrell AW, et al. Metabolism and disposition of Vilanterol, a long-acting beta(2)-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013 Jan;41(1):89-100.

Small volumes of Vilanterol trifenatate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5758202 is an inhibitor targeting Vilanterol trifenatate.